Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 62 of 89 for:    CARBAMAZEPINE AND Psychotropic

Does Gabapentin and Lamotriginel Have Significantly Fewer Side-Effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00007670
Recruitment Status : Completed
First Posted : January 4, 2001
Last Update Posted : January 21, 2009
Sponsor:
Collaborators:
Parke-Davis
Glaxo Wellcome
Information provided by:
VA Office of Research and Development

Brief Summary:
New onset epilepsy in the elderly occurs in 45,000-50,000 elderly patients each year. These patients are especially vulnerable to side effects from medications because of changes caused by the aging process and the fact that these patients often have many common diseases for which they are already receiving medications for so that the likelihood of drug interactions is increased. Two new drugs, gabapentin and lamotrigine, have recently been approved by the FDA as antiepileptic drugs. These drugs have demonstrated efficacy in the treatment of partial onset seizures, the most common seizures in the elderly. These new compounds also have favorable side effect profiles and infrequent drug-drug interactions and, therefore, would be expected to be well-tolerated in the elderly.

Condition or disease Intervention/treatment Phase
Seizures Drug: Carbamazepine Drug: Gabapentin Drug: Lamotrigine Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 720 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Official Title: CSP #428 - Treatment of Seizures in the Elderly Population
Study Start Date : January 1998
Study Completion Date : March 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Seizures





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Veterans 60 years of age or older who have new onset, unprovoked seizures of focal onset, with or without secondary generalization.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00007670


Locations
Show Show 20 study locations
Sponsors and Collaborators
US Department of Veterans Affairs
Parke-Davis
Glaxo Wellcome

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00007670    
Other Study ID Numbers: 428
First Posted: January 4, 2001    Key Record Dates
Last Update Posted: January 21, 2009
Last Verified: February 2007
Keywords provided by VA Office of Research and Development:
gabapentin
lamotrigine
seizures in the elderly
Carbamazepine
Additional relevant MeSH terms:
Layout table for MeSH terms
Carbamazepine
Psychotropic Drugs
Seizures
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Lamotrigine
Gabapentin
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anticonvulsants
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antimanic Agents
Calcium Channel Blockers
Membrane Transport Modulators
Calcium-Regulating Hormones and Agents
Antipsychotic Agents
Sodium Channel Blockers
Analgesics, Non-Narcotic
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers